

The Challenge of Breaking the Status Quo in Hypertension

El desafío de romper el statu quo en hipertensión arterial

JOSÉ BOGGIA

Hypertension is one of the diseases with highest prevalence worldwide, with some disparities depending on the economic development and the demographic composition of the countries. (1) In addition to its high prevalence, its strong impact on the development of cardiovascular disease, renal disease and mortality is well recognized. (2, 3) The influence of hypertension and its consequences on the productive capacity of subjects and the disability-adjusted life-years are reflected worldwide. (3) In some reports, the region of the Rio de la Plata has the highest prevalence and greatest cardiovascular mortality in Latin America. (4, 5)

In this issue of the Journal, Delucchi et al. present the results of the RENATA-2 study. (6) This study uses a randomized sample strategy in 25 districts of 18 provinces of Argentina, exceeding more than three times the number of cities surveyed in the first RENATA study published in 2012. (7) In addition, the methodological virtues of the study include direct measurement of blood pressure, with adequate technique and equipment, and the use of specific questionnaires to evaluate adherence to treatment. The RENATA-2 study stands out in many aspects. It is a national study, conducted by a scientific society that assembles professionals committed with this disease, and is independent of the participation of government authorities. These characteristics make the RENATA-2 a pioneer study in Latin America. In this study, the prevalence of hypertension has a slight upward trend compared with the one measured in 2012: 36.3% (95% CI, 35.1-37.6%) in 2017 versus 33.5% (95% CI, 31.9-34.9) in 2012. Perhaps this information should not be alarming if it is analyzed together with the change in the demographic structure due to population growth and aging. (8) However, other data derived from the RENATA-2 study should be matter of concern, including the crude prevalence of subjects unaware of their hypertensive condition (~40%), and those who are receiving antihypertensive treatment (~50%) and effectively control their disease (~25%). Even more, although the RENATA-2 study does not report age-standardized and sex-standardized prevalence, it provides sex-specific and

age-specific information that shows very poor performance in the diagnosis, treatment and control of the disease in men compared with women and in young subjects compared with older ones. This information differs minimally from the one reported in 2012 and from regional and international publications. (7, 9, 10) Finally, the results of the RENATA-2 study are based on office blood pressure measured on a single day. We know that casual blood pressure measurement with a single blood pressure reading is subject to errors, and that 24-hour ambulatory blood pressure monitoring is the gold standard for the diagnosis of hypertension. This suggests that the real prevalence of hypertension could be even higher if we consider that the proportion of subjects with hidden hypertension in population-based samples ranges between 15% and 20%. (11) Yet, the average prevalence of conventional and ambulatory hypertension is similar. (12)

The RENATA-2 study and the other publications mentioned before reflect that the epidemiological reality of hypertension has not changed or has even worsened, indicating that the health care policies implemented over the past years have failed. This reality goes beyond blood pressure control and also involves other noncommunicable diseases (NCDs) as diabetes and obesity. (8, 13, 14) Only tobacco control has shown partial improvements in some countries. (15, 16) However, over the past years, the Kaiser Permanente Experience restores some hope of improving this disheartening perspective. (17, 18) This experience has demonstrated that breaking some paradigms of the health care system, currently dominated by structures designed to take care of acute diseases and to treat the complications of chronic diseases, can yield positive results. One of the keys of this strategy was to design dynamic strategies according to the possibilities of the system, considering the lowest cost possible, incorporating the actors in the search for solutions and with an almost permanent monitoring of the results obtained with the changes introduced.

Argentina has made substantial contributions to the awareness and treatment of hypertension that are

REV ARGENT CARDIOL 2017;85:303-304. <http://dx.doi.org/10.7775/rac.v85.i4.11685>

SEE RELATED ARTICLE: Rev Argent Cardiol 2017;85:340-346. <http://dx.doi.org/10.7775/rac.v85.i4.11061>

Address for reprints: José Boggia MD, PhD - Unidad de Monitoreo e Investigación en Presión Arterial, Centro de Nefrología - Dpto. de Fisiopatología, Hospital de Clínicas Dr. Manuel Quintela, Universidad de la República. - Avenida Italia 2870, Piso 15, Sala 1 Ap 13, PO-11600 Montevideo, Uruguay. Phone: +598-24809850 - e-mail: jboggia@hc.edu.uy

recognized worldwide. (19) In the current context of knowledge, the great challenge is to contribute improving diagnostic strategies, particularly the efficient treatment for blood pressure control. Surely, this challenge implies breaking down some current status quo paradigms, from medical education to the design of health care policies adjusted by regional realities and a dynamic performance allowing rapid adjustments. Argentina is capable of academic and scientific development in hypertension to face this challenge, and we hope that this will be reflected in the future evaluations of the RENATA study.

Conflicts of interest

None declared.

(See authors' conflicts of interest forms on the website/Supplementary material).

REFERENCES

1. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. *Circulation* 2016;134:441-50.
2. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: The Framingham Study. *Dis Chest* 1969;56:43-52. <http://doi.org/fqs8v9>
3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. *JAMA* 2017;317:827-38. <http://doi.org/cdxw>
4. Armas de Hernández MJ, Armas Padilla MC, Hernández-Hernández R. La hipertensión en Latinoamérica. *Rev Latinoam Hipertens* 2006;1:10-7.
5. Hernández-Hernández R, Silva H, Velasco M, Pellegrini F, Macchia A, Escobedo J, et al. Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study. *J Hypertens [Internet]* 2010;28:24-34. <http://doi.org/cs9b54>
6. Delucchi AM, Majul CR, Vicario A, Cerezo GH, Fábregues G, por los Investigadores del 2° Registro Nacional de Hipertensión Arterial (RENATA 2). National Registry of Hypertension. Epidemiological Characteristics of Hypertension in Argentina. The RENATA 2 study. *Rev Argent Cardiol* 2017;85:340-346.
7. Marin MJ, Fábregues G, Rodríguez PD, Díaz M, Paez O, Alfie J y cols. Registro Nacional de Hipertensión Arterial. Conocimiento, tratamiento y control de la hipertensión arterial: estudio RENATA. *Rev Argent Cardiol* 2012;80:121-9.
8. Kassebaum NJ, Arora M, Barber RM, Bhutta ZA, Brown J, Carter A, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1603-58. <http://doi.org/f3tc2x>
9. Rubinstein AL, Irazola VE, Calandrelli M, Chen C-S, Gutierrez L, Lanas F, et al. Prevalence, awareness, treatment, and control of hypertension in the Southern Cone of Latin America. *Am J Hypertens* 2016;29:1343-52. <http://doi.org/f926kx>
10. Chow CK. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. *JAMA* 2013;310:959. <http://doi.org/f22dt8>
11. Hansen TW, Kikuya M, Thijs L, Björklund-Bodegård K, Kuznetsova T, Ohkubo T, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7030 individuals. *J Hypertens* 2007;25:1554-64. <http://doi.org/dfnwb9>
12. Melgarejo JD, Maestre GE, Thijs L, Asayama K, Boggia JJ, Casiglia E, et al. Prevalence, treatment, and control rates of conventional and ambulatory hypertension across 10 populations in 3 continents. *Hypertension* 2017;70:50-8. <http://doi.org/gbh4rg>
13. Di Cesare M, Bentham J, Stevens GA, Zhou B, Danaei G, Lu Y, et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants. *Lancet* 2016;387:1377-96. <http://doi.org/bd2d>
14. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016;387:1513-30. <http://doi.org/f3rmfb>
15. Abascal W, Esteves E, Goja B, Mora FG, Lorenzo A, Sica A, et al. Tobacco control campaign in Uruguay: A population-based trend analysis. *Lancet* 2012;380:1575-82. <http://doi.org/f2mb4n>
16. (World Health Organization). Global Adult Tobacco Survey data. Fact Sheet Argentina y Uruguay. 2010.
17. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. *JAMA* 2013;310:699. <http://doi.org/f47n3h>
18. Sim JJ, Handler J, Jacobsen SJ, Kanter MH. Systemic implementation strategies to improve hypertension: The Kaiser Permanente Southern California Experience. *Can J Cardiol* 2014;30:544-52. <http://doi.org/f525b7>
19. Basso N. Historia del descubrimiento de la angiotensina. Breve reseña. *Boletín del Consejo Argentino de Hipertensión Arterial de la Sociedad Argentina de Cardiología* 2001;2:10-8.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)

José

2. Surname (Last Name)

Boggia

3. Date

28-July-2017

4. Are you the corresponding author?

Yes No

5. Manuscript Title

El desafío de romper el statu quo en hipertensión arterial

6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution **at any time** receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Are there any relevant conflicts of interest? Yes No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

Are there any relevant conflicts of interest? Yes No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- Yes, the following relationships/conditions/circumstances are present (explain below):
- No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Boggia has nothing to disclose.

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.